Innovent Biologics unveiled early Phase Ib data for IBI3002, a first‑in‑class bispecific antibody targeting IL‑4Rα and TSLP, at the 2026 ATS Annual Meeting. The investigational therapy improved lung function, reduced type 2 inflammatory biomarkers, and showed favorable safety in patients with mild‑to‑moderate asthma.
Written By: Fariha Sameen, PharmD
Reviewed By: Pharmacally Editorial Team
Innovent Biologics has presented early clinical data for IBI3002, a first‑in‑class bispecific antibody targeting IL‑4Rα and thymic stromal lymphopoietin (TSLP), at the 2026 ATS Annual Meeting.
In a randomized, double‑blind, placebo‑controlled Phase Ib study (NCT06213844) conducted in Australia, a single dose of IBI3002 improved pulmonary function and reduced multiple inflammatory biomarkers in patients with mild‑to‑moderate asthma, while maintaining favorable tolerability. Patients receiving IBI3002 showed greater improvement in pre‑bronchodilator FEV1 at Day 36 compared with placebo, alongside larger reductions in fractional exhaled nitric oxide (FeNO), peripheral eosinophils, immunoglobulin E (IgE), and thymus and activation‑regulated chemokine (TARC).
IBI3002 simultaneously blocks IL‑4Rα and TSLP, two key drivers of type 2 airway inflammation. Unlike current biologics such as dupilumab (IL‑4Rα) and tezepelumab (TSLP), which target these pathways separately, IBI3002’s dual‑target approach aims to suppress both upstream inflammatory signaling and downstream immune activation.
Preclinical findings showed the therapy reduced airway inflammation and immune cell infiltration more effectively than either comparator, supporting the potential for broader disease control in heterogeneous asthma populations.
“The data support the potential of IBI3002 to address persistent unmet needs in asthma patients with suboptimal disease control,” said Dr. Lei Qian, Chief R&D Officer of General Biomedicine at Innovent Biologics. He added that the company plans to advance development in both asthma and atopic dermatitis, while expanding its broader bispecific antibody pipeline.
Innovent also highlighted additional next‑generation bispecific candidates, including IBI3038 and IBI3031, expected to enter clinical development in 2026. The pipeline reflects a mechanism‑driven strategy focused on fibrosis, inflammation, and immune dysregulation.
The Phase Ib findings position IBI3002 as a potential competitor in the growing asthma biologics market, where therapies targeting IL‑4, IL‑13, and TSLP pathways continue to expand across severe and uncontrolled disease settings.
Reference
About the Writer
Fariha Sameen, PharmD (LinkedIn), is a clinical pharmacy professional with hands-on experience in patient counselling, medication review, therapeutic monitoring, and clinical documentation across multiple departments. She has experience identifying and assessing drug-related problems and supporting medication safety practices. Her interests include pharmacovigilance, ADR reporting, clinical research, and medical writing focused on clear, evidence-based communication.